News

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

The role of the pharmacist, managed care pharmacist job satisfaction and artificial intelligence were among the topics that Susan A. Cantrell, CEO of the Academy of Managed Care Pharmacy, discussed with Perry Cohen, Pharm.D., in this episode of "Conversations with Perry and Friends."

The deals that drugmakers have struck in response to Trump's most favored nation pricing policies may not be affected, partly because the president has authority to impose tariffs under other statutes.

Early pharmacy leadership helps health systems build safe, sustainable cell and gene therapy programs, aligning contracts, workflows, regulations and payer realities.

Health systems learn why cell and gene therapy success depends on workflows, staffing, and finances—not just science—and how to build them.

Zimbabwe has become one of the first countries in the world to launch a national lenacapavir program, introducing the twice-yearly injectable HIV prevention drug as part of its ongoing efforts to reduce new infections and end AIDS as a public health threat.

In this video interview, Joseph Kleiman, president of Buzz Health, says that patients should always “do their homework” to see if they are paying the lowest possible price for their prescription, whether that’s through TrumpRx or another website.

Researchers say a modest price cut would make semaglutide cost-effective for secondary prevention of cardiovascular disease in the United States.

In this Q&A, Jessica Vazzaz explained what evidence supports sonic sleep aids, who benefits and what payers should demand before covering sleep-disorder apps.

FDA reviews tirabrutinib for relapsed/refractory primary CNS lymphoma under accelerated approval, with promising phase 2 response rates and a Dec. 2026 decision.

Leaders of the smaller PBMs say they’ve always been transparent, pass-through companies, and complying with the new law’s reporting requirements is not a heavy lift.

A conversation with Joseph Kleiman emphasizes price transparency, consumer research and the need for consistent pricing and drug availability.

A study of older women suggests that greater muscle strength lowers the risk of death, regardless of other factors like sedentary behavior.

A number of recent studies suggests that shingles vaccine has benefits beyond just protecting against shingles.

A multicenter Swedish study finds influenza vaccination during immunotherapy is associated with longer survival, particularly in people being treated for melanoma, without increasing immune-related side effects.

Jessica Vazzaz, a doctoral researcher and tutor in psychology at the University of Sussex, shared that health plans should require large, well-designed randomized trials before covering sonic sleep aids. She added that benefits are likely fair and could vary by individual, making it critical to understand who these tools actually help and under what conditions.

Citing updated scientific evidence, the FDA has revised safety labels for six menopause hormone therapies, removing previous boxed warnings to better reflect current understanding of their risks and benefits for women in early menopause

Real-world China study uses Markov modeling to show surgery may beat radiotherapy on cost per QALY for ESCC, despite higher upfront costs.

New research at Mount Sinai explains how influenza infections increase the risk of heart attack through a specific immune pathway.

Senators Elizabeth Warren and Josh Hawley have introduced bipartisan legislation that addresses a system that they say adds costs and leaves independent doctors and pharmacists unable to compete.

GLP-1 drugs boost health but challenge plastic surgery as rapid weight loss triggers facial sag and skin changes, prompting new options and lifestyle guidance.

Aetna Medicaid and the National Association of Community Health Centers have partnered to reduce high blood pressure rates among Medicaid members in select states by expanding community-based care.

A new economic evaluation finds that pairing extended counseling with a brief course of nicotine replacement therapy offers the best value for health systems integrating smoking cessation into lung cancer screening.

A new study finds that the recombinant zoster vaccine was associated with a 51% lower risk of dementia. This was seen across age and racial and ethnic groups, but the risk reduction was stronger in women compared with men.

A conversation with Gil Yosipovitch, M.D., explores why itch worsens at night, how it rivals chronic pain in quality-of-life impact, and why better assessment of nighttime itch and sleep disruption is urgently needed.

Clinicians weigh sonic sleep tools: who benefits, how to use phone-based audio safely and why CBT-I stays first-line for insomnia.

During an investor call, CVS Health executives said the new legislation requiring changes in PBM business practices was manageable, but they expressed some concern about CMS’s Medicare advanced rate notice.